SINOPHARM(01099),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

01099 SINOPHARM

Not Yet Opened 03-23 16:08:09

20.420

-0.440

-2.11%

High20.820	Low20.140	Vol11.95M
Open20.600	D1 Closing20.860	Amplitude3.26%
Mkt Cap63.73B	Tradable Cap27.40B	Total Shares3.12B
T/O243.72M	T/O Rate0.89%	Tradable Shares1.34B
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"01099","market":"HK","secType":"STK","nameCN":"SINOPHARM","latestPrice":20.42,"timestamp":1774253289004,"preClose":20.86,"halted":0,"volume":11954309,"delay":0,"changeRate":-0.021093000958772663,"floatShares":1341810740,"shares":3121000000,"eps":2.259128,"marketStatus":"Not Yet Opened","change":-0.44,"latestTime":"03-23 16:08:09","open":20.6,"high":20.82,"low":20.14,"amount":243720004,"amplitude":0.032598,"askPrice":20.44,"askSize":61600,"bidPrice":20.42,"bidSize":16000,"shortable":3,"etf":0,"ttmEps":2.479965,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1774315800000},"marketStatusCode":0,"adr":0,"listingDate":1253635200000,"exchange":"SEHK","adjPreClose":20.86,"dividendRate":0.036161,"openAndCloseTimeList":[[1774229400000,1774238400000],[1774242000000,1774252800000]],"volumeRatio":2.540452267063026,"lotSize":400,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"SNP.HK","impliedVol":0.3242,"impliedVolPercentile":0.9309},"requestUrl":"/m/hq/s/01099","defaultTab":"news","newsList":[{"id":"2621403507","title":"Sinopharm FY2025 net profit rose 3.94% to RMB 10,834 million as net cash from operating activities climbed 22.45% to RMB 14,138 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2621403507","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621403507?lang=en_us&edition=fundamental","pubTime":"2026-03-23 08:51","pubTimestamp":1774227097,"startTime":"0","endTime":"0","summary":"Sinopharm FY2025 net profit rose 3.94% to RMB 10,834 million as net cash from operating activities climbed 22.45% to RMB 14,138 million. Sinopharm published a 2025 annual results presentation reporting business revenue of RMB575.17 billion, up 1.62%.Net profits were RMB10.83 billion, up 3.94%, while net profits attributable to owners of the parent were RMB7.16 billion, up 1.5%.Gross profit margin was 7.25%  and net profit margin was 1.88% .Segment revenue included pharmaceutical distribution of RMB435.39 billion  and medical device distribution of RMB115.54 billion .Retail pharmacy revenue was RMB38.38 billion  and management said wholesale-retail integration and a dual-brand strategy supported growth, while it managed lower-efficiency device businesses with long payment terms to reduce risk.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL5kWYpj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1197","LU0640798160.USD","01099","BK1500","LU1115378108.SGD","BK1515"],"gpt_icon":0},{"id":"1148475248","title":"SINOPHARM Reports Annual Earnings with 1.5% Rise in Net Profit Attributable to Owners","url":"https://stock-news.laohu8.com/highlight/detail?id=1148475248","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148475248?lang=en_us&edition=fundamental","pubTime":"2026-03-23 07:23","pubTimestamp":1774221800,"startTime":"0","endTime":"0","summary":"SINOPHARM (01099) announced its annual results for the year ended December 31, 2025. The Group recorded revenue of RMB 575.168 billion, representing a decrease of 1.6% year-on-year. Profit...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0640798160.USD","BK4585","VIG","BK1500","BK1515","BK4588","LU1115378108.SGD","BK1197","01099"],"gpt_icon":0},{"id":"2621818744","title":"BRIEF-Sinopharm Group Posts FY Profit Attributable Of RMB7.16 BLN","url":"https://stock-news.laohu8.com/highlight/detail?id=2621818744","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621818744?lang=en_us&edition=fundamental","pubTime":"2026-03-23 06:18","pubTimestamp":1774217901,"startTime":"0","endTime":"0","summary":"BRIEF-Sinopharm Group Posts FY Profit Attributable Of RMB7.16 BLNMarch 23  - Sinopharm Group Co Ltd 1099.HK:FINAL DIVIDEND OF RMB0.69 PER ORDINARY SHARE IS TO BE PROPOSEDFY PROFIT ATTRIBUTABLE RMB7.16 BILLIONFY REVENUE RMB575.17 BILLIONFurther company coverage: 1099.HK ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260322:nFWN4080Z0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0640798160.USD","BK1515","BK1500","BK1197","01099","LU1115378108.SGD"],"gpt_icon":0},{"id":"2621892744","title":"Sinopharm Group proposes final dividend of RMB 0.69 per share","url":"https://stock-news.laohu8.com/highlight/detail?id=2621892744","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621892744?lang=en_us&edition=fundamental","pubTime":"2026-03-23 06:16","pubTimestamp":1774217815,"startTime":"0","endTime":"0","summary":"Shareholder approval is scheduled for June 18, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sinopharm Group Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 22, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260322:nNDL3PQNfP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","01099","BK1197","LU1115378108.SGD","BK1500","LU0640798160.USD"],"gpt_icon":0},{"id":"2621410717","title":"Sinopharm Group - FY Profit Attributable RMB7.16 Bln","url":"https://stock-news.laohu8.com/highlight/detail?id=2621410717","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621410717?lang=en_us&edition=fundamental","pubTime":"2026-03-23 06:14","pubTimestamp":1774217671,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260322:nFWN4080Z0:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1115378108.SGD","BK1500","LU0640798160.USD","BK1515","BK1197","01099"],"gpt_icon":0},{"id":"2621073741","title":"Sinopharm Group -  Final Dividend of RMB0.69 per Ordinary Share Is to Be Proposed","url":"https://stock-news.laohu8.com/highlight/detail?id=2621073741","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621073741?lang=en_us&edition=fundamental","pubTime":"2026-03-23 06:14","pubTimestamp":1774217671,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260322:nFWN4080Z0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1115378108.SGD","LU0640798160.USD","BK1500","01099","BK1197","BK1515"],"gpt_icon":0},{"id":"2620735379","title":"Sinopharm Group (SEHK:1099) Valuation Check As Recent Share Price Moves Draw Investor Attention","url":"https://stock-news.laohu8.com/highlight/detail?id=2620735379","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620735379?lang=en_us&edition=fundamental","pubTime":"2026-03-20 16:12","pubTimestamp":1773994379,"startTime":"0","endTime":"0","summary":"Why Sinopharm Group is on investors’ radar today\nSinopharm Group (SEHK:1099) has drawn attention after recent share price moves, with a 1-day and past-week return of a 1.0% decline, alongside mixed performance over the month and past 3 months.\nSee our latest analysis for Sinopharm Group.\nAt a share price of HK$20.84, Sinopharm Group’s recent share price return has softened over the past month, although the 90 day and year to date share price returns remain positive while longer term total...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6031000-choice2-main-header/1585186857496","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6031000-choice2-main-header/1585186857496"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/healthcare/hkg-1099/sinopharm-group-shares/news/sinopharm-group-sehk1099-valuation-check-as-recent-share-pri","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/healthcare/hkg-1099/sinopharm-group-shares/news/sinopharm-group-sehk1099-valuation-check-as-recent-share-pri","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0640798160.USD","LU1115378108.SGD","BK1500","01099","BK1197","BK1515","DCF"],"gpt_icon":0},{"id":"1141027450","title":"SINOPHARM Subsidiary Reports Annual Operating Profit of RMB 1.25 Billion, Up 2.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=1141027450","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141027450?lang=en_us&edition=fundamental","pubTime":"2026-03-19 21:38","pubTimestamp":1773927493,"startTime":"0","endTime":"0","summary":"SINOPHARM (01099) announced that its subsidiary, China National Medical Device Co., Ltd., recorded annual revenue of RMB 74.89 billion for the year ended December 31, 2025, representing a decrease of...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099","BK1197","LU0640798160.USD","LU1115378108.SGD","BK1500","BK1515"],"gpt_icon":0},{"id":"2620225119","title":"Sinopharm subsidiary CNMDC posts RMB 74.89 billion 2025 revenue and RMB 506.76 million comprehensive income attributable to parent owners","url":"https://stock-news.laohu8.com/highlight/detail?id=2620225119","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620225119?lang=en_us&edition=fundamental","pubTime":"2026-03-19 21:26","pubTimestamp":1773926816,"startTime":"0","endTime":"0","summary":"Sinopharm subsidiary CNMDC posts RMB 74.89 billion 2025 revenue and RMB 506.76 million comprehensive income attributable to parent owners. Sinopharm subsidiary China National Medical Device  reported revenue of RMB 74.89 billion.Operating profit at CNMDC was RMB 1.25 billion.Total comprehensive income attributable to owners of the parent company rose 25.64% to RMB 0.51 billion.Total equity attributable to owners of the parent company increased 5.27% to RMB 8.3 billion.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sinopharm Group Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 19, 2026, and is solely responsible for th","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL1mnZlj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","LU1115378108.SGD","BK1197","BK1500","01099","LU0640798160.USD"],"gpt_icon":0},{"id":"2620022385","title":"OSR subsidiary Woori IO signs NDA with Sinopharm to explore China opportunities","url":"https://stock-news.laohu8.com/highlight/detail?id=2620022385","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620022385?lang=en_us&edition=fundamental","pubTime":"2026-03-19 20:55","pubTimestamp":1773924915,"startTime":"0","endTime":"0","summary":"Woori IO, a subsidiary of OSR Holdings, signed a mutual NDA with Sinopharm Group Beijing Huahong to exchange confidential information on Woori IO’s near-infrared glucose monitoring technology.The NDA framework covers evaluation of potential regulatory, clinical and commercial pathways in China.Sinopharm Group reported 2024 revenue of about USD 81 billion.China’s diabetes device market is projected to exceed USD 12 billion by 2032, according to Research and Markets.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDLbb7krB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","LU0640798160.USD","OSRH","LU1115378108.SGD","BK1197","BK1500","BK4139","01099"],"gpt_icon":0},{"id":"1127561911","title":"Sinopharm Group (01099.HK): Subsidiary Sinopharm Accord Posts 76.8% Surge in 2025 Net Profit Despite 1.29% Dip in Revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=1127561911","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127561911?lang=en_us&edition=fundamental","pubTime":"2026-03-18 06:20","pubTimestamp":1773786036,"startTime":"0","endTime":"0","summary":"Hong Kong – 17 March 2026 – Sinopharm Group Co. Ltd. (01099.HK) has released unaudited preliminary results for its Shenzhen-listed subsidiary, China National Accord Medicines Corporation Ltd....","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"gpt_icon":0},{"id":"2620406403","title":"Sinopharm Accord net profit rises 76.8% to RMB1.14 billion in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2620406403","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620406403?lang=en_us&edition=fundamental","pubTime":"2026-03-18 06:14","pubTimestamp":1773785640,"startTime":"0","endTime":"0","summary":"Sinopharm said subsidiary Sinopharm Accord reported 2025 revenue of RMB73.42 billion, down 1.29%. Sinopharm Accord reported net profit attributable to shareholders of RMB1.14 billion, up 76.8%, and basic earnings per share of RMB2.04, up 77.39%. Operating profit rose to RMB1.51 billion, more than doubled from a year earlier. Sinopharm Accord’s retail unit Guoda Drugstore reported revenue of RMB20.98 billion, down 6.16%, and net profit of RMB-217 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sinopharm Group Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 17, 2026, and is solely responsible for the information c","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL9ZswZH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["000028","BK0196","BK1500","BK1515","BK0082","BK0185","BK0250","LU0640798160.USD","BK0188","LU1115378108.SGD","BK0028","BK0010","BK1197","BK0175","01099"],"gpt_icon":0},{"id":"2620471406","title":"Sinopharm Group FY Revenue RMB 73,416 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2620471406","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620471406?lang=en_us&edition=fundamental","pubTime":"2026-03-18 06:12","pubTimestamp":1773785561,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nPLXE6D20E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0640798160.USD","BK1500","01099","BK1197","LU1115378108.SGD","BK1515"],"gpt_icon":0},{"id":"2620442784","title":"Sinopharm Group  Stock Sheds 1.2% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2620442784","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620442784?lang=en_us&edition=fundamental","pubTime":"2026-03-17 16:46","pubTimestamp":1773737160,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Sinopharm Group Co. Ltd. slipped 1.2% to 21.18 Hong Kong dollars on what proved to be an all-around great trading session for the Hong Kong stock market, with the Hang Seng Index rising 0.1% to 25868.54.The stock's fall snapped a three-day winning streak.Sinopharm Group Co. Ltd. closed 5.2% short of its 52-week high of HK$22.34, which the company reached Feb. 25.The stock underperformed when compared to some of its competitors, as Shanghai Fosun Pharmaceutical  Co. Ltd. rose 0.4%.Trading volume totaled 5.1 million shares, compared to the 50-day average of 5.5 million shares.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099","BK1515","LU0640798160.USD","BK1500","LU1115378108.SGD","SHTDY","BK4175","BK1197"],"gpt_icon":0},{"id":"2619453679","title":"Sinopharm Group  Stock Rallies 1.4% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2619453679","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619453679?lang=en_us&edition=fundamental","pubTime":"2026-03-16 16:33","pubTimestamp":1773649980,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Sinopharm Group Co. Ltd. rallied 1.4% to 21.44 Hong Kong dollars on what proved to be an all-around positive trading session for the Hong Kong stock market, with the Hang Seng Index rising 1.4% to 25834.02.This was the stock's third consecutive day of gains.Sinopharm Group Co. Ltd. closed 4.0% below its 52-week high of HK$22.34, which the company reached Feb. 25.The stock outperformed some of its competitors, as Shanghai Fosun Pharmaceutical  Co. Ltd. rose 1.1%.Trading volume totaled 5.5 million shares, compared to the 50-day average of 5.4 million shares.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1197","LU0640798160.USD","SHTDY","LU1115378108.SGD","BK4175","01099","BK1500"],"gpt_icon":0},{"id":"2618184896","title":"Sinopharm Group  Stock Rises 1.3% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2618184896","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618184896?lang=en_us&edition=fundamental","pubTime":"2026-03-12 16:33","pubTimestamp":1773304380,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Sinopharm Group Co. Ltd. rose 1.3% to 21.06 Hong Kong dollars on what proved to be an all-around poor trading session for the Hong Kong stock market, with the Hang Seng Index falling 0.7% to 25716.76.Sinopharm Group Co. Ltd. closed 5.7% short of its 52-week high of HK$22.34, which the company achieved Feb. 25.The stock outperformed some of its competitors, as Shanghai Fosun Pharmaceutical  Co. Ltd. fell 0.9%.Trading volume totaled 7.2 million shares, compared to the 50-day average of 5.4 million shares.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4175","SHTDY","BK1515","LU1115378108.SGD","BK1500","LU0640798160.USD","01099","BK1197"],"gpt_icon":0},{"id":"1141756822","title":"Lazard Asset Management Increases Stake in SINOPHARM by 3.64 Million Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1141756822","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141756822?lang=en_us&edition=fundamental","pubTime":"2026-03-10 19:10","pubTimestamp":1773141038,"startTime":"0","endTime":"0","summary":"According to the latest data from the Hong Kong Stock Exchange, on March 4, Lazard Asset Management LLC purchased an additional 3.64 million shares of SINOPHARM (01099) at a price of HK$20.6296 per...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1197","BK1500","01099","BK1515","LU1115378108.SGD","LU0640798160.USD"],"gpt_icon":0},{"id":"1135632537","title":"SINOPHARM (01099) Schedules 20 Mar 2026 Board Meeting to Approve FY2025 Results and Dividend Proposal","url":"https://stock-news.laohu8.com/highlight/detail?id=1135632537","media":"Bulletin Express","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1135632537?lang=en_us&edition=fundamental","pubTime":"2026-03-10 16:43","pubTimestamp":1773132215,"startTime":"0","endTime":"0","summary":"Sinopharm Group Co. Ltd. (stock code: 01099) has announced that its board of directors will convene on 20 March 2026 to review and approve the consolidated financial results for the twelve months...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"gpt_icon":0},{"id":"2618421980","title":"Sinopharm Group  Stock Rallies 1.5% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2618421980","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618421980?lang=en_us&edition=fundamental","pubTime":"2026-03-10 16:33","pubTimestamp":1773131580,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Sinopharm Group Co. Ltd. rose 1.5% to 20.94 Hong Kong dollars on what proved to be an all-around great trading session for the Hong Kong stock market, with the Hang Seng Index rising 2.2% to 25959.90.The stock's rise snapped a two-day losing streak.Sinopharm Group Co. Ltd. closed 6.3% short of its 52-week high of HK$22.34, which the company reached Feb. 25.The stock underperformed when compared to some of its competitors, as Shanghai Fosun Pharmaceutical  Co. Ltd. rose 1.5%.Trading volume totaled 6.8 million shares, compared to the 50-day average of 5.3 million shares.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1500","SHTDY","BK1515","LU0640798160.USD","LU1115378108.SGD","BK4175","01099","BK1197"],"gpt_icon":0},{"id":"1197997993","title":"SINOPHARM [01099] Announces February 2026 Monthly Return on Securities Movements","url":"https://stock-news.laohu8.com/highlight/detail?id=1197997993","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197997993?lang=en_us&edition=fundamental","pubTime":"2026-03-05 06:25","pubTimestamp":1772663120,"startTime":"0","endTime":"0","summary":"SINOPHARM [01099] disclosed its monthly return for equity securities for the period ended 28 February 2026. The updated figures show that authorized share capital reached 3.12 billion shares (RMB 1...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sinopharmgroup.com.cn","stockEarnings":[{"period":"1week","weight":-0.0476},{"period":"1month","weight":-0.0267},{"period":"3month","weight":0.0371},{"period":"6month","weight":0.1068},{"period":"1year","weight":0.0958},{"period":"ytd","weight":0.0504}],"compareEarnings":[{"period":"1week","weight":-0.0562},{"period":"1month","weight":-0.0769},{"period":"3month","weight":-0.054},{"period":"6month","weight":-0.0806},{"period":"1year","weight":0.0292},{"period":"ytd","weight":-0.0487}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Sinopharm Group Co Ltd is a China-based company principally engaged in the wholesale and retail of pharmaceutical and healthcare products and medical devices. The Company operates its business through four segments. The Pharmaceutical Distribution segment provides distribution, logistics and other value-added services to domestic and foreign pharmaceutical and health product manufacturers and other suppliers. The Device Distribution segment distributes medical devices to customers. The Pharmaceutical Retail Business segment owns a network of retail pharmacies that are directly operated or franchised. The Other Business segment is engaged in the manufacture and sale of pharmaceuticals, chemical reagents and laboratory supplies.","yearOnYearQuotes":[{"month":1,"riseRate":0.588235,"avgChangeRate":0.004643},{"month":2,"riseRate":0.588235,"avgChangeRate":0.029413},{"month":3,"riseRate":0.470588,"avgChangeRate":0.00762},{"month":4,"riseRate":0.4375,"avgChangeRate":0.022869},{"month":5,"riseRate":0.625,"avgChangeRate":-0.004548},{"month":6,"riseRate":0.4375,"avgChangeRate":-0.005852},{"month":7,"riseRate":0.5,"avgChangeRate":-0.015111},{"month":8,"riseRate":0.4375,"avgChangeRate":0.012101},{"month":9,"riseRate":0.4375,"avgChangeRate":-0.011177},{"month":10,"riseRate":0.647059,"avgChangeRate":0.042295},{"month":11,"riseRate":0.470588,"avgChangeRate":-0.007287},{"month":12,"riseRate":0.529412,"avgChangeRate":-0.004122}],"exchange":"SEHK","name":"SINOPHARM","nameEN":"SINOPHARM"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"SINOPHARM(01099),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest SINOPHARM(01099) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"SINOPHARM,01099,SINOPHARM股票,SINOPHARM股票老虎,SINOPHARM股票老虎国际,SINOPHARM行情,SINOPHARM股票行情,SINOPHARM股价,SINOPHARM股市,SINOPHARM股票价格,SINOPHARM股票交易,SINOPHARM股票购买,SINOPHARM股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"SINOPHARM(01099),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest SINOPHARM(01099) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}